Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience & Cognition, UMR-S 1172, European Genomic Institute for Diabetes (EGID), 59000 Lille, France.
Univ. Lille, CHU Lille, Inserm U1190, EGID, Institut Pasteur de Lille, 59000 Lille, France.
Cell Metab. 2022 Jul 5;34(7):1054-1063.e7. doi: 10.1016/j.cmet.2022.06.002. Epub 2022 Jun 17.
Liraglutide, an anti-diabetic drug and agonist of the glucagon-like peptide one receptor (GLP1R), has recently been approved to treat obesity in individuals with or without type 2 diabetes. Despite its extensive metabolic benefits, the mechanism and site of action of liraglutide remain unclear. Here, we demonstrate that liraglutide is shuttled to target cells in the mouse hypothalamus by specialized ependymoglial cells called tanycytes, bypassing the blood-brain barrier. Selectively silencing GLP1R in tanycytes or inhibiting tanycytic transcytosis by botulinum neurotoxin expression not only hampers liraglutide transport into the brain and its activation of target hypothalamic neurons, but also blocks its anti-obesity effects on food intake, body weight and fat mass, and fatty acid oxidation. Collectively, these striking data indicate that the liraglutide-induced activation of hypothalamic neurons and its downstream metabolic effects are mediated by its tanycytic transport into the mediobasal hypothalamus, strengthening the notion of tanycytes as key regulators of metabolic homeostasis.
利拉鲁肽是一种抗糖尿病药物,也是胰高血糖素样肽-1 受体 (GLP1R) 的激动剂,最近已被批准用于治疗有或没有 2 型糖尿病的肥胖症患者。尽管其具有广泛的代谢益处,但利拉鲁肽的作用机制和作用部位仍不清楚。在这里,我们证明利拉鲁肽通过称为室管膜细胞的特殊室管膜细胞被转运到小鼠下丘脑的靶细胞中,绕过血脑屏障。选择性沉默室管膜细胞中的 GLP1R 或通过表达肉毒杆菌神经毒素抑制室管膜细胞的转胞吞作用,不仅阻碍了利拉鲁肽进入大脑并激活靶下丘脑神经元,还阻断了其对食物摄入、体重和脂肪量以及脂肪酸氧化的抗肥胖作用。总的来说,这些引人注目的数据表明,利拉鲁肽激活下丘脑神经元及其下游代谢作用是通过其进入中脑基底部下丘脑的室管膜细胞转运介导的,这加强了室管膜细胞作为代谢稳态关键调节剂的概念。